Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 5/20 | 0.39 |
| ▸ | HEXA | P06865 | 1/20 | 0.38 |
| ▸ | HEXB | P07686 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.36 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.35 |
| ▸ | SIK1 | P57059 | 1/20 | 0.35 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.34 |
| ▸ | RXRA | P19793 | 3/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | STK4 | Q13043 | 1/20 | 0.33 |
| ▸ | STK3 | Q13188 | 1/20 | 0.33 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.33 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863472 | 0.99 | HTT (0.38) | HTTHASPINHEXAHEXBDYRK2 | |
| SCHEMBL7868927 | 0.99 | HTT (0.38) | HTTHASPINHEXAHEXBDYRK2 | |
| SCHEMBL7868806 | 0.96 | HTT (0.40) | HTTHASPINHEXAHEXBDYRK2 | |
| SCHEMBL7871622 | 0.83 | HTT (0.36) | HTT | |
| SCHEMBL7863477 | 0.82 | ALDH1A1 (0.45) | HTTHEXAHEXBTDP1 | |
| SCHEMBL7872398 | 0.81 | TDP1 (0.42) | HTTTDP1PLK1 | |
| Hydrochloric Acid SCHEMBL7871546 | 0.80 | TDP1 (0.41) | HTTTDP1PLK1 | |
| Hydrochloric Acid SCHEMBL7871692 | 0.80 | MEN1 (0.37) | HTTTDP1 | |
| SCHEMBL7871625 | 0.80 | TDP1 (0.38) | HTTTDP1PLK1 | |
| SCHEMBL7863443 | 0.79 | FAAH (0.38) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | HTT 710/4885HASPIN 3077/4885HEXA 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.